Treatment with tezepelumab (Tezspire) can substantially reduce or eliminate oral corticosteroid (OCS) use in adults with OCS-dependent severe asthma, according to new Phase 3 WAYFINDER results presented at ATS 2025.
Treatment with tezepelumab (Tezspire) can substantially reduce or eliminate oral corticosteroid (OCS) use in adults with OCS-dependent severe asthma, according to new Phase 3 WAYFINDER results presented at ATS 2025.
Read More
Results from the BATURA Phase IIIb trial found that albuterol–budesonide (AirSupra) demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone
Read More
Healthy Lungs California will expand its early lung cancer screening initiative thanks to a partnership between the University of California Lung Cancer Consortium and AstraZeneca.
Read More
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More
The treatment, designed for patients with advanced EGFR-mutated NSCLC resistant to prior therapies, could offer a new option pending FDA approval.
Read More
AstraZeneca’s Imfinzi (durvalumab) has been approved in the United States for the treatment of adult patients with limited-stage small cell lung cancer.
Read More
AstraZeneca’s inhaled anti-inflammatory rescue medication demonstrated significant benefit compared to albuterol in a phase IIIb trial.
Read More
The FDA has approved osimertinib for adult patients with stage III NSCLC whose tumors have specific EGFR mutations, following chemoradiation therapy.
Read More
The approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read More
The unexpected finding of pre-existing T-cell reactivity to the AstraZeneca and Janssen vaccines may explain why some people rarely developed thrombotic thrombocytopenia syndrome after vaccination.
Read More
New data presented at ATS 2024 show the potential of Tezspire to play a role in the future treatment of COPD.
Read More
The additional indication is for pediatric patients aged 6-11 with severe eosinophilic asthma.
Read More
Starting June 1, eligible patients will pay no more than $35 per month for all AstraZeneca US inhaled respiratory medicines.
Read More
The inhaler contains a short-acting beta2-agonist to help relax the smooth muscles of the airways and an inhaled corticosteroid to help decrease inflammation in the lungs, treating both symptoms and inflammation.
Read More
AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Read More
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.
Read MoreThe company’s lead investigational vaccine candidate, IVX-A12, is a potential first-in-class, phase III-ready vaccine targeting both RSV and human metapneumovirus.
Read More
Findings from a multinational study demonstrated that 92% of patients using benralizumab could safely reduce inhaled steroid dose, and more than 60% could stop all use.
Read More
AstraZeneca’s Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.
Read More
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the EU as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
Read More
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors, according to Phase 3 trial data.
Read More
The US CDC has issued advice for healthcare providers to navigate the shortage of nirsevimab (Beyfortus), used to immunize infants from RSV.
Read More
The FDA will review AstraZeneca’s sNDA for Tagrisso (osimertinib) plus chemotherapy for EGFRm non-small cell lung cancer (NSCLC).
Read More
Sanofi issued an advisory to notify healthcare providers and consumers of a “unprecedented” and “higher than anticipated” demand for its recently-approved RSV monoclonal antibody, nirsevimab-alip (Beyfortus).
Read More
